SAM
EBS icon

Shell Asset Management’s Emergent Biosolutions EBS Stock Holding History

Shell Asset Management’s Portfolio EBS Stock Details EBS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-46,970
Closed -$160K – 1257
2023
Q3 		$160K Buy
46,970
+41,493
+758% +$230K 0.01% 971
2023
Q2 		$40K Sell
5,477
-2,737
-33% -$25.4K ﹤0.01% 1232
2023
Q1 		$85K Sell
8,214
-29
-0.4% -$351 ﹤0.01% 1140
2022
Q4 		$97K Sell
8,243
-1,673
-17% -$25.9K ﹤0.01% 1159
2022
Q3 		$208K Sell
9,916
-2,600
-21% -$72.4K 0.01% 996
2022
Q2 		$388K Buy
12,516
+21
+0.2% +$717 0.01% 848
2022
Q1 		$513K Sell
12,495
-1,848
-13% -$81.5K 0.01% 801
2021
Q4 		$623K Buy
14,343
+67
+0.5% +$3.03K 0.01% 795
2021
Q3 		$715K Sell
14,276
-610
-4% -$36.9K 0.02% 677
2021
Q2 		$938K Buy
14,886
+3,201
+27% +$206K 0.02% 607
2021
Q1 		$1.09M Sell
11,685
-70
-0.6% -$7.17K 0.02% 507
2020
Q4 		$1.05M Hold
11,755
– – 0.02% 495
2020
Q3 		$1.22M Hold
11,755
– – 0.03% 418
2020
Q2 		$930K Sell
11,755
-151
-1% -$11.3K 0.02% 455
2020
Q1 		$689K Sell
11,906
-181
-1% -$10.4K 0.02% 539
2019
Q4 		$652K Sell
12,087
-285
-2% -$15.5K 0.01% 750
2019
Q3 		$647K Sell
12,372
-107
-0.9% -$4.99K 0.01% 763
2019
Q2 		$603K Sell
12,479
-286
-2% -$13.7K 0.01% 831
2019
Q1 		$645K Hold
12,765
– – 0.01% 787
2018
Q4 		$757K Sell
12,765
-1,100
-8% -$70.9K 0.02% 641
2018
Q3 		$913K Hold
13,865
– – 0.02% 712
2018
Q2 		$700K Sell
13,865
-743
-5% -$38.7K 0.01% 831
2018
Q1 		$769K Hold
14,608
– – 0.02% 775
2017
Q4 		$679K Sell
14,608
-3,639
-20% -$153K 0.01% 804
2017
Q3 		$738K Sell
18,247
-500
-3% -$18.1K 0.02% 722
2017
Q2 		$636K Hold
18,747
– – 0.01% 821
2017
Q1 		$544K Sell
18,747
-1,311
-7% -$39.9K 0.01% 872
2016
Q4 		$659K Sell
20,058
-175
-0.9% -$5.25K 0.02% 798
2016
Q3 		$638K Buy
+20,233
New +$588K 0.01% 780

Other funds holding EBS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Hotchkis & Wiley Capital Management
Hotchkis & Wiley Capital Management Los Angeles, California $34.3B AUM 22.63% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Shell Asset Management's EBS Position: Q4 2023 in Review

Shell Asset Management sold out of Emergent Biosolutions (EBS) in Q4 2023, closing a stake of 46,970 shares — an estimated $160K sold.

Shell Asset Management first reported a position in EBS in Q3 2016 and held it in 29 quarters. The position peaked at $1.22M in Q3 2020. 134 funds tracked by Wall St. Rank hold EBS as of Q4 2023.

  • Shell Asset Management reported no remaining Emergent Biosolutions position as of Q4 2023 after selling out during the quarter.
  • Shell Asset Management sold 46,970 Emergent Biosolutions shares in Q4 2023, an estimated $160K.
  • Shell Asset Management first reported a position in Emergent Biosolutions in Q3 2016 and held it in 29 quarters.
  • Shell Asset Management's Emergent Biosolutions position peaked at $1.22M in Q3 2020.
  • 134 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q4 2023.

Based on Shell Asset Management's 13F filing for Q4 2023, filed 14 Feb 2024.